Remdesivir for Prevention of Covid-19 Progression Among n | UPDATES IN MEDICINE
Remdesivir for Prevention of Covid-19 Progression
Among nonhospitalized patients with Covid-19–related symptoms that began less than a week previously, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. Adverse effects in the remdesivir group were similar to those in the placebo group.
